<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02329080</url>
  </required_header>
  <id_info>
    <org_study_id>IELSG42</org_study_id>
    <nct_id>NCT02329080</nct_id>
  </id_info>
  <brief_title>New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement</brief_title>
  <official_title>An International Phase II Trial Assessing Tolerability and Efficacy of Sequential Methotrexate-Aracytin-based Combination and R-ICE Combination, Followed by HD Chemotherapy Supported by ASCT, in Patients With Systemic B-cell Lymphoma With CNS Involvement at Diagnosis or Relapse (MARIETTA Regimen)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Extranodal Lymphoma Study Group (IELSG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Extranodal Lymphoma Study Group (IELSG)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open, non comparative, multicentre phase II trial, to evaluate the efficacy and
      feasibility of a new sequential combination of HD-MTX-AraC-based chemoimmunotherapy, followed
      by R-ICE regimen, and by high-dose chemotherapy supported by ASCT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment includes 6 courses of chemoimmunotherapy, the first three courses with an high dose
      methotrexate-based combination (MATRIX) followed by other three courses of R-ICE combination
      and finally a BCNU-thiotepa- containing conditioning and subsequent autologous stem cell
      transplantation.

      MATRIX (courses 1, 2, 3):

      Rituximab 375 mg/m2, Methotrexate 3.5 g/m2, Cytarabine 2 g/m2, Folinic rescue 15 mg/m2,
      Thiotepa 30 mg/m2, Intrathecal liposomial cytarabine 50 mg, rHuG-CSF 2,5 g/kg s.c.

      R-ICE (courses 4, 5, 6):

      Rituximab 375 mg/m2, Etoposide 100 mg/m2/d , Ifosfamide 5 g/m2, Intrathecal liposomial
      cytarabine 50 mg
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete remission rate</measure>
    <time_frame>at the end of chemoimmunotherapy (up to 22-24 weeks from treatment start)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response duration</measure>
    <time_frame>after the 2nd, 4th and 6th courses of chemoimmunotherapy and 45 days after ASCT. During follow up every 3 months for 2 years, than every 6 months for 3 years and yearly thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>from entry onto trial until death from any cause or date of the last visit of follow-up (5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with adverse events</measure>
    <time_frame>from time informed consent is given until 30 days after end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>MATRIX - R-ICE - Conditioning and ASCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MATRIX (courses 1,2,3): Rituximab 375 mg/m2 d0/Methotrexate 3.5 g/m2 d1/Cytarabine 2 g/m2 d2 &amp; d3/Thiotepa 30 mg/m2 d4/Liposomial Cytarabine 50 mg* d5
R-ICE (courses 4,5,6):Rituximab 375 mg/m2 d1/Etoposide 100 mg/m2 d1,d2, d3/Ifosfamide 5 g/m2 d2/Carboplatin 5 AUC d2/Liposomial Cytarabine 50 mg* d4
*If liposomal cytarabine is not available, standard intrathecal chemotherapy with methotrexate 10 mg + cytarabine 40 mg + hydrocortisone 50 mg can be administered. Oral steroids are suggested for 2-3 days after intrathecal liposomial cytarabine delivery to prevent chemical or aseptic meningitis/ arachnoiditis.
Conditioning and ASCT: BCNU (carmustine)** 400 mg/m2 d-6/Thiotepa 5 mg/kg d-5 &amp; d-4 ASCT: 5 x 106 CD34+cells/kg d0
**In case of BCNU unavailability, the recommended conditioning regimen (Phase IV) is: Thiotepa 5 mg/kg d-6 &amp; d-5/Busulfan 3.2 mg/kg d-4,d -3,d-2/Clonazepam 2 mg/d d-4,d -3,d-2 ASCT: 5 x 106 CD34+cells/kg d0</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>methotrexate 3.5 g/m2 on day 1 courses 1, 2,3 of MATRIX regimen</description>
    <arm_group_label>MATRIX - R-ICE - Conditioning and ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab 375 mg/m2 as conventional IV infusion on day 0 courses 1, 2,3 (MATRIX regimen) and on day 1 courses 4,5,6 (R-ICE)</description>
    <arm_group_label>MATRIX - R-ICE - Conditioning and ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Cytarabine 2 g/m2 every 12 hours, in 3-hr infusion on days 2,3 courses 1, 2,3 (MATRIX regimen)</description>
    <arm_group_label>MATRIX - R-ICE - Conditioning and ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Thiotepa 30 mg/m2 in 30 minutes infusion on day 4 courses 1, 2,3 (MATRIX regimen) and 5 mg/kg in 250 ml of saline sol. in 2-hrs infusion every 12 hours on day -5 and -4 of conditioning and ASCT</description>
    <arm_group_label>MATRIX - R-ICE - Conditioning and ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposomial cytarabine</intervention_name>
    <description>Intrathecal liposomial cytarabine 50 mg on day 5 courses 1, 2,3 (MATRIX regimen) and on day 4 courses 4,5,6 (R-ICE)</description>
    <arm_group_label>MATRIX - R-ICE - Conditioning and ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Etoposide 100 mg/m2/d in 500 mL saline sol. in 30 minutes on day 1-2-3 courses 4,5,6 (R-ICE)</description>
    <arm_group_label>MATRIX - R-ICE - Conditioning and ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Ifosfamide 5 g/m2 in 1.000 mL saline sol. in 24-hour infusion on day 2 courses 4,5,6 (R-ICE)</description>
    <arm_group_label>MATRIX - R-ICE - Conditioning and ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carmustine</intervention_name>
    <description>BCNU (carmustine) 400 mg/m2 in 500 mL glucose 5% sol. in 1-hr infusion on day-6 of conditioning and ASCT</description>
    <arm_group_label>MATRIX - R-ICE - Conditioning and ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>whole brain radiotherapy</intervention_name>
    <description>whole-brain irradiation 36 Gy + tumor- bed boost 10 Gy in patients with residual disease in the parenchymal brain/cerebellum.</description>
    <arm_group_label>MATRIX - R-ICE - Conditioning and ASCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed diagnosis of diffuse large B-cell lymphoma

          2. CNS involvement (brain, meninges, cranial nerves, eyes and/or spinal cord) at
             diagnosis (concomitant to extra-CNS disease) or relapse after conventional
             chemo(-immuno)therapy

          3. Diagnosis of CNS involvement either by brain biopsy or CSF cytology examination.
             Neuroimaging alone is acceptable when stereotactic biopsy is formally contraindicated
             or when the disease has been previously histologically documented in other areas and
             the CNS localization is concomitant with a diffuse progression of systemic disease.

          4. No previous treatment with high-dose methotrexate-based chemotherapy and/or brain
             irradiation. One-two courses of R-CHOP combination as upfront therapy are admitted in
             patients with large amount and/or extensive extra-CNS disease that could condition
             prognosis in an early phase of treatment. Local investigator decides if initial R-CHOP
             is needed based on patient's conditions

          5. Age 18-70 years

          6. ECOG performance status 0-3

          7. Adequate bone marrow (Platelets count ≥100.000/mm3, hemoglobin ≥9 g/dL, neutrophils
             count≥1.500/mm3), renal (creatinine clearance ≥60 mL/min), cardiac (LVEF ≥50%), and
             hepatic function (total serum bilirubine ≤3 mg/dL, AST/ALT and GGT ≤2.5 per upper
             normal limit value), unless the abnormality is due to lymphoma infiltration

          8. Absence of HIV infection and of detectable HCV-RNA and/or HBsAg and/or HBV-DNA

          9. No concurrent malignancies. Previous malignancies are accepted if surgically cured or
             if there was no evidence of disease in the last 3 years at a regular follow-up

         10. Absence of any familial, sociological or geographical condition potentially hampering
             compliance with the study protocol and follow-up schedule

         11. Female patients must be non-pregnant and non-lactating. Sexually active patients of
             childbearing potential must implement adequate contraceptive measures during study
             participation

         12. No treatment with other experimental drugs within the 6 weeks previous to enrolment

         13. Given written informed consent prior to any study specific procedures, with the
             understanding that the patient has the right to withdraw from the study at any time,
             without any prejudice. Informed consent signed by a patient's guardian is acceptable
             if the patient is not able to decide inclusion in the study due to cognitive
             impairment

        Exclusion Criteria:

          1. Other lymphoma categories other than diffuse large B-cell lymphoma. In particular,
             patients with primary mediastinal lymphoma, intravascular large B-cell lymphoma or
             leg-type large B-cell lymphoma are excluded.

          2. Patients with positive flow cytometry examination of the CSF, but negative results in
             CSF conventional cytology, and without any other evidence of CNS disease.

          3. Patients with exclusive CNS disease at presentation (primary CNS lymphoma) are
             excluded

          4. Previous treatment with support of autologous or allogeneic stem cells/bone marrow
             transplantation.

          5. Symptomatic coronary artery disease, cardiac arrhythmias not well controlled with
             medication or myocardial infarction within the last 6 months (New York Heart
             Association Class III or IV heart disease)

          6. Any other serious medical condition which could impair the ability of the patient to
             participate in the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrés JM Ferreri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>IELSG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emanuele Zucca, MD</last_name>
    <phone>+41918119040</phone>
    <email>ielsg@eoc.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Facultni nemocnice</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Janikova</last_name>
    </contact>
    <investigator>
      <last_name>Andrea Janikova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FNKV (Facultni Nemocnice Kralovske Vinohrady)</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Mocikova</last_name>
    </contact>
    <investigator>
      <last_name>Heidi Mocikova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vseobecna facultni nemocnice v Praze</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Pytlik</last_name>
    </contact>
    <investigator>
      <last_name>Robert Pytlik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Rossi</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppe Rossi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Ematologia e CTMO, PO Businco</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppina Cabras</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppina Cabras</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRST Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerardo Musuraca</last_name>
    </contact>
    <investigator>
      <last_name>Gerardo Musuraca</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Ematoliga Ospedale dell'Angelo</name>
      <address>
        <city>Mestre</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renato Bassan</last_name>
    </contact>
    <investigator>
      <last_name>Renato Bassan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Liliana Devizzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Cecilia Goldaniga</last_name>
    </contact>
    <investigator>
      <last_name>Maria Cecilia Goldaniga</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Raffaele H Scientific Institute</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres Ferreri, MD</last_name>
      <email>ferreri.andres@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Andrés JM Ferreri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Narni</last_name>
    </contact>
    <investigator>
      <last_name>Franco Narni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCDU Ematologia</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianluca Gaidano</last_name>
    </contact>
    <investigator>
      <last_name>Gianluca Gaidano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia ed Immunologia Clinica - AO di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renato Zambello</last_name>
    </contact>
    <investigator>
      <last_name>Renato Zambello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Oncoematologia Ospedale Tortora</name>
      <address>
        <city>Pagani</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catello Califano</last_name>
    </contact>
    <investigator>
      <last_name>Catello Califano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Villa Sofia - Cervello</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caterina Patti</last_name>
    </contact>
    <investigator>
      <last_name>Caterina Patti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia AOU</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Re</last_name>
    </contact>
    <investigator>
      <last_name>Francesca Re</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia Ospedale S.Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Cellini</last_name>
    </contact>
    <investigator>
      <last_name>Claudia Cellini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Bianchi-Melacrino-Morelli, Divisione di Ematologia</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caterina Stelitano, MD</last_name>
    </contact>
    <investigator>
      <last_name>Caterina Stelitano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova, Azienda Ospedaliera di Reggio Emilia</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiorella Ilariucci</last_name>
    </contact>
    <investigator>
      <last_name>Fiorella Ilariucci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia Università La Sapienza</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Martelli</last_name>
    </contact>
    <investigator>
      <last_name>Maurizio Martelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Regina Elena (IFO)</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Palombi</last_name>
    </contact>
    <investigator>
      <last_name>Francesca Palombi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Bio-Medico</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ombretta Annibali</last_name>
    </contact>
    <investigator>
      <last_name>Ombretta Annibali</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Casa Sollievo Della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Cascavilla</last_name>
    </contact>
    <investigator>
      <last_name>Nicola Cascavilla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Senese</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Fabbri</last_name>
    </contact>
    <investigator>
      <last_name>Alberto Fabbri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO S.Maria di Terni</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Marina Liberati</last_name>
    </contact>
    <investigator>
      <last_name>Anna Marina Liberati</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SC Ematologia AO Città della Salute e della Scienza</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Botto</last_name>
    </contact>
    <investigator>
      <last_name>Barbara Botto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Ematologia Ospedale Panico</name>
      <address>
        <city>Tricase</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Pavone</last_name>
    </contact>
    <investigator>
      <last_name>Vincenzo Pavone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Santa Maria della Misericordia</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Zaja</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Zaja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia Policlinico Rossi</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Achille Ambrosetti</last_name>
    </contact>
    <investigator>
      <last_name>Achille Ambrosetti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia Ospedale S. Bortolo</name>
      <address>
        <city>Vicenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Frezzato</last_name>
    </contact>
    <investigator>
      <last_name>Maurizio Frezzato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanette Doorduijn</last_name>
    </contact>
    <investigator>
      <last_name>Jeanette Doorduijn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beatson Cancer Center</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pam Mc Kay</last_name>
    </contact>
    <investigator>
      <last_name>Pam Mc Kay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liverpool Aintree</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffery Smith</last_name>
    </contact>
    <investigator>
      <last_name>Jeffery Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLH University College London Hospitals NHS foundation trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Cwynarski</last_name>
    </contact>
    <investigator>
      <last_name>Kate Cwynarski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Linton</last_name>
    </contact>
    <investigator>
      <last_name>Kim Linton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Davies</last_name>
    </contact>
    <investigator>
      <last_name>Andrew Davies</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2014</study_first_submitted>
  <study_first_submitted_qc>December 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2014</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Carmustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

